Skip to main content
Log In
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest Content
Archive
For authors
About
Podcasts
Search for this keyword
Advanced search
Close
More
Main menu
Latest Content
Archive
For authors
About
Podcasts
Log in
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
Archive
Volume 8, Issue 2
Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I/II trial
Email alerts
Article metrics
Article menu
Article
Text
Article
info
Citation
Tools
Share
Rapid Responses
Article
metrics
Alerts
PDF
Lupus
Original research
Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I/II trial
Online download statistics by month:
Online download statistics by month: October 2022 to December 2022
Abstract
Full
Pdf
Oct 2022
264
264
97
Nov 2022
763
754
231
Dec 2022
195374
195375
581
Total
196401
196393
909
Read the full text or download the PDF:
Subscribe
Log in
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
PDF